BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 23137584)

  • 1. Rheumatic Disease Clinics of North America. Drug safety: managing innovation in rheumatology. Foreword.
    Weisman MH
    Rheum Dis Clin North Am; 2012 Nov; 38(4):ix-x. PubMed ID: 23137584
    [No Abstract]   [Full Text] [Related]  

  • 2. Refining drug safety in rheumatology.
    Cush JJ; Dao KH
    Rheum Dis Clin North Am; 2012 Nov; 38(4):xi-xiv. PubMed ID: 23137585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Biosimilars].
    Burmester GR; Müller-Ladner U
    Z Rheumatol; 2015 Oct; 74(8):670-1. PubMed ID: 26450433
    [No Abstract]   [Full Text] [Related]  

  • 4. Recent advances in Pediatric Rheumatology: July 2015-June 2016.
    Sharma A; Vignesh P; Jindal AK; Gupta A
    Int J Rheum Dis; 2017 Apr; 20(4):504-509. PubMed ID: 28205425
    [No Abstract]   [Full Text] [Related]  

  • 5. TPMT testing in rheumatology: any better than routine monitoring?
    Payne K; Newman W; Fargher E; Tricker K; Bruce IN; Ollier WE
    Rheumatology (Oxford); 2007 May; 46(5):727-9. PubMed ID: 17255139
    [No Abstract]   [Full Text] [Related]  

  • 6. [New trends in rheumatology. The Danish Society of Rheumatology].
    Andersen LS; Gam AN; Hansen A; Kollerup G; Rasmussen C; Rasmussen JM; Schiøttz-Christensen B; Slot O; Thamsborg G
    Ugeskr Laeger; 2003 Mar; 165(12):1255. PubMed ID: 12701305
    [No Abstract]   [Full Text] [Related]  

  • 7. [Current status of methotrexate].
    Fiehn C
    Z Rheumatol; 2011 Feb; 70(2):99-100. PubMed ID: 21312022
    [No Abstract]   [Full Text] [Related]  

  • 8. Neutropenia in the Elderly: A Rheumatology Perspective.
    Yeoh SA; Fox C; Hull R
    Drugs Aging; 2016 Aug; 33(8):585-601. PubMed ID: 27402172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Continuous quick development of rheumatology].
    Madsen OR; Terslev L; Tarp U; Jacobsen S; Ostergaard M
    Ugeskr Laeger; 2009 Mar; 171(13):1092. PubMed ID: 19321087
    [No Abstract]   [Full Text] [Related]  

  • 10. Advances in targeted therapies XII. Preface.
    Breedveld FC; Kalden JR; Smolen JS
    Ann Rheum Dis; 2011 Mar; 70 Suppl 1():i1. PubMed ID: 21339210
    [No Abstract]   [Full Text] [Related]  

  • 11. The possible clinical application of pharmacogenetics in rheumatology.
    Ferraccioli G
    J Rheumatol; 2003 Dec; 30(12):2517-20. PubMed ID: 14719186
    [No Abstract]   [Full Text] [Related]  

  • 12. Disease-modifying antirheumatic drugs.
    Belavic J
    Nursing; 2010 Nov; 40(11):20. PubMed ID: 20975424
    [No Abstract]   [Full Text] [Related]  

  • 13. [Rheumatology: present and future].
    Braun J
    Dtsch Med Wochenschr; 2012 Sep; 137(36):1735. PubMed ID: 22933193
    [No Abstract]   [Full Text] [Related]  

  • 14. Rheumatology. 3. Modern drug therapies and current guidelines in rheumatology nursing.
    Hill J; Reay N
    Nurs Times; 2002 Mar 7-13; 98(10):41-4. PubMed ID: 11921625
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacotherapy Pearls in Rheumatology for the Care of Older Adult Patients: Focus on Oral Disease-Modifying Antirheumatic Drugs and the Newest Small Molecule Inhibitors.
    Betancourt BY; Biehl A; Katz JD; Subedi A
    Rheum Dis Clin North Am; 2018 Aug; 44(3):371-391. PubMed ID: 30001781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Off-label therapy in rheumatology].
    Krüger K; Sieper J
    Z Rheumatol; 2012 Feb; 71(2):99-100. PubMed ID: 22370799
    [No Abstract]   [Full Text] [Related]  

  • 17. Communicating the risk of side effects to rheumatic patients.
    Martin RW
    Rheum Dis Clin North Am; 2012 Nov; 38(4):653-62. PubMed ID: 23137575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pregnancy and rheumatic diseases.
    Malviya AN
    J Assoc Physicians India; 1994 Feb; 42(2):178. PubMed ID: 7860501
    [No Abstract]   [Full Text] [Related]  

  • 19. COVID-19 and rheumatology: Reflecting on the first wave and preparing for the second wave.
    Fardanesh A; Byravan S; Moorthy A; Tahir H
    Int J Rheum Dis; 2021 Jan; 24(1):7-9. PubMed ID: 33459529
    [No Abstract]   [Full Text] [Related]  

  • 20. Standardizing assessment of adverse effects in rheumatology clinical trials. Status of OMERACT Toxicity Working Group March 2000: towards a common understanding of comparative toxicity/safety profiles for antirheumatic therapies.
    Woodworth TG; Furst DE; Strand V; Kempeni J; Fenner H; Lau CS; Miller F; Day R; Lipani J; Brooks P
    J Rheumatol; 2001 May; 28(5):1163-9. PubMed ID: 11361207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.